- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
CCM Research analyst, Mohammad Sharifzadeh, Ph.D., CFA, has written an update report on Starpharma Holdings Ltd.
Starpharma Holdings, Ltd. (OTCQX: SPHRY) (ASX: SPL) is an Australian-based company engaged in the development and application of dendrimer nanotechnologies as drugs and in other life science applications. Starpharma's business strategy is to use dendrimer-based nanotechnology to discover, develop and commercialize pharmaceuticals for serious human diseases and in life sciences.
In the report the analyst states "with the increasing global awareness of the HIV/AIDS problem and the accelerating endeavors at the international, governmental, civil social groups, and even individuals' levels to prevent and treat this devastating epidemic as quick as possible, Starpharma's VivaGel stands at the forefront of the global HIV/AIDS prevention strategies."
The analyst continues "we agree with Starpharma's management that acquisition of DNT results in valuable synergies including more U.S. presence, extensive IP portfolio, road to commercialization, and a more diversified product base."
Regarding Starpharma's external financing the analyst notes, "They have a strong cash position which can support their operating and R&D expenses should there be a shortfall in revenues. Starpharma has almost a debt free balance sheet with substantial equity which provides the company with the opportunity of external financing should the need arises."
A free copy of the report can be found at http://www.ccmopportunitybase.com .
CCM Research, a division of Cronus Capital Markets, Inc. subscribes to the "Standards for Independent Research Providers" and the principles contained in the Analyst/Corporate Issuer Guidelines jointly promulgated by the CFA Institute and the National Investor Relations Institute, described at: http://www.cfainstitute.org and http://www.niri.org .
Cronus Capital Markets, Inc., through its CCM Consulting Division, entered into a one year $30,000.00 contract with the company to assist it with the creation and execution of information-based strategies to overcome market inefficiencies that are commonplace for the vast majority of public companies, including share illiquidity and stagnant market capitalization.
About Cronus Capital Markets
Cronus Capital Markets (CCM) is a global investment information firm who strategically produces and introduces, through various forms of analytics and worldwide distribution, information on equity market opportunities. CCM's equity indexes receive international attention and represent important new benchmarks of growth.
For more information, please click here
Cronus Capital Markets
(416) 368-3700 ext 223
Copyright © Market WireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Industrial Nanotech, Inc. Provides Shareholder Update August 22nd, 2016
Leading Advanced Materials Manufacturer Pixelligent Closes $10.4 Million in Funding: Capital Will Boost Capacity for North American Manufacturing, Drive Asian Expansion, and Continue Innovation in Solid State Lighting and OLED Display Applications August 16th, 2016
Harris & Harris Group to Host a Shareholder Update Call, Including a Presentation by One of Its Precision Health and Medicine Portfolio Companies, Muses Labs, Inc., on August 23, 2016 August 16th, 2016
50 years after the release of the film 'Fantastic Voyage,' science upstages fiction: Science upstages fiction with nanorobotic agents designed to travel in the human body to treat cancer August 25th, 2016
Graphene under pressure August 26th, 2016
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers